Asynchronous reformation of individual kallikrein-related secretory proteinases in rat submandibular glands following degranulation by cyclocytidine.
Time scales for the reformation of the secretory granules in granular tubules and their constituent proteinases were assessed after inducing a massive degranulation by intraperitoneal injection of cyclocytidine in conscious animals. The minimum working dose of cyclocytidine to produce the maximum degranulation and depletion of proteinase activity, at 3 h after injection, was 75 mg/kg. Histologically, although most granular tubule cells then appeared to be extensively degranulated, isolated individual cells showing little or no degranulation always persisted. Acinar cells also showed some depletion of secretory material. At 15 h after injecting cyclocytidine the formation of new granules had begun in the granular tubule cells, but it was not extensive or uniform in adjacent cells; however, the acinar cells already appeared to be regranulated. The pattern of granule reformation in granular tubule cells progressed gradually, so that 7-10 days after cyclocytidine-induced degranulation the cells were mostly packed with granules and showed similar appearances to those of normal resting control glands. Individual proteinases in extracts of the glands were assayed specifically using fluorogenic oligopeptide amidase substrates, with and without appropriate inhibitors. This revealed a 95% reduction in total proteinase activity 3 h after cyclocytidine (75 mg/kg). In the same extracts, acinar peroxidase was reduced by 28%. Peroxidase levels recovered to control values within 15 h after cyclocytidine but recovery of proteinases progressed more gradually and did not occur uniformly for the different constituent proteinases. Tissue kallikrein (rK1) showed the most rapid recovery and had reached levels approaching normal within 3 days.(ABSTRACT TRUNCATED AT 250 WORDS)
Proctor
G B
GB
Department of Oral Pathology, King's College School of Medicine and Dentistry, Rayne Institute, London, U.K.
Shori
D K
DK
Chan
K M
KM
Garrett
J R
JR
D003504:Ancitabine / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D002265:Carboxylic Ester Hydrolases / Q000032:analysis / Q000096:biosynthesis / Q000187:drug effects; D015550:Cell Degranulation / Q000187:drug effects*; D003594:Cytoplasmic Granules / Q000187:drug effects* / Q000201:enzymology* / Q000648:ultrastructure; D007525:Isoelectric Focusing; D007610:Kallikreins / Q000032:analysis / Q000096:biosynthesis* / Q000187:drug effects*; D008297:Male; D010544:Peroxidases / Q000032:analysis / Q000096:biosynthesis / Q000187:drug effects; D051381:Rats; D017208:Rats, Wistar; D013363:Submandibular Gland / Q000166:cytology* / Q000187:drug effects* / Q000201:enzymology; D020840:Tissue Kallikreins
D003504:Ancitabine; D010544:Peroxidases; C019724:arginine esterase; D002265:Carboxylic Ester Hydrolases; D007610:Kallikreins; D020840:Tissue Kallikreins